SGLT2i and GLP-1RA therapies are linked to a reduced risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD is associated with higher cardiovascular disease risk and is more common in T2D patients. A study found that both SGLT2i and GLP-1RA were associated with a decreased risk of MACE, and SGLT2i was also linked to a decreased risk of heart failure hospitalization. The study supports current guidelines recommending GLP-1RA as first-line therapy for T2D and NAFLD and shows the potential of SGLT-2i for cardiovascular disease prevention regardless of NAFLD status.
Source link
Glucose-Lowering Medications Decrease MACE Risk for Patients With T2D and MASLD
